•  
  •  
 

Subject Area

Radiology and Imaging Sciences

Article Type

Original Study

Abstract

Objective To evaluate the role of serum ischemia-modified albumin (IMA) level in cerebrovascular stroke and its relation to the severity or prognosis in patients with acute cerebrovascular disease. Background It was recently demonstrated that IMA levels increase in the acute phase of cerebrovascular diseases. Yet the data regarding IMA levels in various types of cerebrovascular events are still insufficient. Patients and methods A case–control study on 100 consecutive patients and 75 normal individuals as controls was conducted. National Institute of Health Stroke Scale and Glasgow Coma Scale were assessed at admission time. Lesion volume was calculated using computed tomography scan. IMA levels were measured at the same time using the available chemical method. Patients were followed up after 3 months, and the modified Rankin scale (MRS) was evaluated. Results IMA was significantly higher in the patient group than in the control group (96.83 ± 12.01 vs. 44.47 ± 5.28, P < 0.001). There were significantly higher mean values of IMA in patients with ischemic stroke than those with hemorrhagic stroke (P = 0.036). Regarding severity, serum IMA concentrations were positively correlated with National Institute of Health Stroke Scale (r = 0.252, P = 0.01) and lesion volume calculated by computed tomography scan (r = 0.21, P = 0.04) but inversely correlated with Glasgow Coma Scale score (r = −0.227, P = 0.02). Regarding prognosis, on applying MRS 3 months after stroke, this study showed that MRS had no statistically significant correlation with IMA (r = 0.01, P = 0.938). Conclusion IMA levels are higher in patients with acute cerebrovascular disease compared with healthy individuals. The level of IMA is higher in patients with ischemic stroke than those with hemorrhagic stroke. IMA can be used as an indicator of stroke severity.

Download

Share

COinS